Abstract 3788: BBO-8520, a first-in-class direct dual inhibitor of GTP-bound (ON) and GDP-bound (OFF) KRASG12C, exhibits robust efficacy in non-small cell lung cancer preclinical models
2025; American Association for Cancer Research; Volume: 85; Issue: 8_Supplement_1 Linguagem: Inglês
10.1158/1538-7445.am2025-3788
ISSN1538-7445
AutoresJames P. Stice, Anna E. Maciag, Alok K. Sharma, Albert H. Chan, Ken Lin, Devansh Singh, Marcin Dyba, Yue Yang, Saman Setoodeh, Cathy Zhang, Bryan D. Smith, Dana Rabara, Zuhui Zhang, Erik K. Larsen, John-Paul Denson, Michela Ranieri, Mary Meynardie, Rui Xu, Felice C. Lightstone, Kwok‐Kin Wong, Andrew Stephen, Keshi Wang, Dhirendra K. Simanshu, Kerstin W. Sinkevicius, Dwight V. Nissley, Bin Wang, Eli Wallace, Frank McCormick, Pedro J. Beltran,
Tópico(s)Metabolism, Diabetes, and Cancer
Referência(s)